Compare Endeavour Silver Corp (EXK) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Endeavour Silver Corp trades at $7.96 (market cap $2.44B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.1× Endeavour Silver Corp's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 26 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EXK | SYRE | |
|---|---|---|
Market Cap | $2.44B | $7.52B |
Volume | 5,983,279 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $108.92 |
52-Week Low | $7.07 | $22.18 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $2.44B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.24, down 3.51% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of $119.1 million in 2025 but improved to a net profit of $66 million in 2026, driven by revenue growth from $468 million to $737 million. Recent news highlights operational progress at the Terronera mine and a temporary mechanical issue at Guanacevi, while analyst consensus remains strongly positive with 11 buy ratings.
The outlook for EXK hinges on successful execution of mine expansions and favorable silver prices, offering growth potential, but risks include operational disruptions, commodity price volatility, and high valuation multiples. Investors should weigh the strong analyst support against near-term profitability challenges and market sentiment.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
